- After its drug candidate for overactive bladder (OAB), TC-5214, failed to reach one of its co-primary endpoints in a 768-patient Phase 2b clinical trial, Targacept (TRGT) pulls the plug on the development program.
- TC-5214 achieved a statistically significant reduction in micturation frequency but failed to achieve statistical significance on episodes of urinary incontinence over 24 hours after 12 weeks of treatment.
- CEO Dr. Stephen A. Hill says, "Although TC-5214 provided dose-dependent efficacy on several endpoints during the course of treatment, the results were not compelling enough to justify the compound's continued development in overactive bladder."
- TRGT shares are down 32% AH on light volume (2,600 shares).
Targacept axes OAB drug development after Phase 2 fails
From other sites
at CNBC.com (Dec 13, 2011)
at CNBC.com (Nov 15, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs